{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:45:20Z","timestamp":1791812720975,"version":"4.3.4"},"reference-count":11,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"\n OBJECTIVE<\/jats:title>\n Atomoxetine is indicated for the treatment of attention-deficit\/hyperactivity disorder, and fluoxetine is commonly used for treating depression. Variable dosing per body weight is required in children, and the commercially available capsules do not offer the required flexibility and potential for customization. The objective of this study was to evaluate the physicochemical stability of atomoxetine hydrochloride and fluoxetine hydrochloride oral anhydrous extemporaneously compounded suspensions.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n An anhydrous suspension of atomoxetine hydrochloride was prepared from commercially available capsules at a 4-mg\/mL concentration, and an anhydrous suspension of fluoxetine hydrochloride was prepared from pure drug powder at a concentration of 10 mg\/mL. The extemporaneously compounded suspensions were prepared according to standardized formulas and methods of preparation. Samples were stored at refrigerated and controlled room temperatures for 6 months. The physicochemical properties of the samples were analyzed and characterized on days 0, 14, 30, 60, 90, and 180. A robust stability-indicating ultra-performance liquid chromatography assay method was validated and employed.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The samples remained consistent in appearance and color, with atomoxetine forming a pale-yellow suspension and fluoxetine yielding an off-white to faint beige suspension. Both anhydrous suspensions remained within the \u00b110% potency specification. The percent concentration relative to labelled concentration (potency) was at or above 96.5% for atomoxetine and at or above 96.8% for fluoxetine.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION<\/jats:title>\n Beyond-use dates of 6 months at both refrigerated and room temperature conditions have been established for the atomoxetine 4-mg\/mL anhydrous suspension and the fluoxetine 10-mg\/mL anhydrous suspension.<\/jats:p>\n <\/jats:sec>","DOI":"10.5863\/jppt-25-00010","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:50:38Z","timestamp":1791809438000},"page":"598-607","source":"Crossref","is-referenced-by-count":0,"title":["Chemical Stability of Atomoxetine Hydrochloride and Fluoxetine Hydrochloride Oral Anhydrous Extemporaneously Compounded Suspensions"],"prefix":"10.5863","volume":"31","author":[{"given":"Kendice","family":"Ip","sequence":"first","affiliation":[{"name":"Research and Development (KI, MC, DB), PCCA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtaney","family":"Davis","sequence":"additional","affiliation":[{"name":"Formulations (CD), PCCA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Vu","sequence":"additional","affiliation":[{"name":"Formulations (CD), PCCA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashoda V.","family":"Pramar","sequence":"additional","affiliation":[{"name":"College of Pharmacy (YVP), Xavier University of Louisiana, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Research and Development (KI, MC, DB), PCCA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Banov","sequence":"additional","affiliation":[{"name":"Research and Development (KI, MC, DB), PCCA, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"JPPT-25-00010-b01","article-title":"Atomoxetine hydrochloride [dosage and administration]","unstructured":"RxList. Atomoxetine hydrochloride [dosage and administration]. Accessed April 22, 2024. www.RxList.com"},{"issue":"9","key":"JPPT-25-00010-b02","series-title":"Pharmaceuticals","first-page":"1091","article-title":"The role of pharmaceutical compounding in promoting medication adherence","volume":"15","author":"Carvalho","year":"2022","unstructured":"Carvalho M, Almeida IF. The role of pharmaceutical compounding in promoting medication adherence. Pharmaceuticals. 2022;15(9):1091."},{"issue":"4","key":"JPPT-25-00010-b03","series-title":"Int J Pharm Compd","first-page":"321","article-title":"Atomoxetine 4 mg\/mL Oral Solution\/Suspension","volume":"25","author":"Loyd","year":"2021","unstructured":"Loyd A Jr. Atomoxetine 4 mg\/mL Oral Solution\/Suspension. Int J Pharm Compd. 2021;25(4):321."},{"key":"JPPT-25-00010-b04","article-title":"Fluoxetine hydrochloride [dosage and administration]","unstructured":"RxList. Fluoxetine hydrochloride [dosage and administration]. Accessed April 22, 2024. www.RxList.com"},{"key":"JPPT-25-00010-b05","series-title":"Trissel\u2019s Stability of Compounded Formulations","author":"Trissel","year":"2018","unstructured":"Trissel LA. Trissel\u2019s Stability of Compounded Formulations. 6th ed. Washington, DC: American Pharmacists Association; 2018."},{"key":"JPPT-25-00010-b06","series-title":"Am J Hosp Pharm","first-page":"1342","article-title":"Stability of fluoxetine hydrochloride in fluoxetine solution diluted with common pharmaceutical diluents","volume":"51","author":"Peterson","year":"1994","unstructured":"Peterson JA, Risley DS, Anderson PN, et al. Stability of fluoxetine hydrochloride in fluoxetine solution diluted with common pharmaceutical diluents. Am J Hosp Pharm. 1994;51:1342\u20131345."},{"issue":"4","key":"JPPT-25-00010-b07","series-title":"Int J Pharm Compd","first-page":"327","article-title":"Stability of extemporaneous oral tramadol, fluoxetine, and doxycycline Suspensions in SyrSpend SF PH4","volume":"24","author":"Espana","year":"2020","unstructured":"Espana B, Joseph-Tornabene F, Jaquet C, Perrot S, Prouillac C. Stability of extemporaneous oral tramadol, fluoxetine, and doxycycline Suspensions in SyrSpend SF PH4. Int J Pharm Compd. 2020;24(4):327\u2013336."},{"key":"JPPT-25-00010-b08","series-title":"United States Pharmacopeia 43-National Formulary 38","first-page":"1961","article-title":"Fluoxetine Oral Solution","year":"2023","unstructured":"United States Pharmacopeial Convention, Inc. Fluoxetine Oral Solution . In: United States Pharmacopeial Convention, Inc. United States Pharmacopeia 43-National Formulary 38. Rockville, MD: United States Pharmacopeial Convention, Inc; 2023:1961."},{"issue":"11","key":"JPPT-25-00010-b09","series-title":"Pharmaceutics","first-page":"2642","article-title":"Analysis of the physical characteristics of an anhydrous vehicle for compounded pediatric oral liquids","volume":"15","author":"Banov","year":"2023","unstructured":"Banov D, Liu Y, Ip K, et al. Analysis of the physical characteristics of an anhydrous vehicle for compounded pediatric oral liquids. Pharmaceutics. 2023;15(11):2642."},{"key":"JPPT-25-00010-b10","series-title":"United States Pharmacopeia 43-National Formulary 38","first-page":"8044","article-title":"Stability Considerations in Dispensing Practice","year":"2023","unstructured":"United States Pharmacopeial Convention, Inc. Stability Considerations in Dispensing Practice. In: United States Pharmacopeial Convention, Inc, ed. United States Pharmacopeia 43-National Formulary 38. Rockville, MD: United States Pharmacopeial Convention, Inc; 2023: 8044."},{"key":"JPPT-25-00010-b11","series-title":"Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies","author":"De Carvalho","year":"2013","unstructured":"De Carvalho R, Jo\u00e3o M. Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies [doctoral thesis]. London, UK: University College London; 2013."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/5\/article-p598.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/5\/article-p598.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/5\/article-p598.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:50:39Z","timestamp":1791809439000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/5\/article-p598.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":11,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00010","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}